Dataset Information


Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.

ABSTRACT: Detection of specific chromosomal abnormalities by FISH and metaphase cytogenetics allows risk stratification in multiple myeloma; however, gene expression profiling (GEP) based signatures may enable more specific risk categorization. We examined the utility of 2 GEP-based risk stratification systems among patients undergoing initial therapy with lenalidomide in the context of a phase 3 trial. Among 45 patients studied at baseline, 7 (16%) and 10 (22%), respectively, were high-risk using the GEP70 and GEP15 signatures. The median overall survival for the GEP70 high-risk group was 19 months versus not reached for the rest (hazard ratio = 14.1). Although the medians were not reached, the GEP15 also predicted a poor outcome among the high-risk patients. The C-statistic for the GEP70, GEP15, and FISH based risk stratification systems was 0.74, 0.7, and 0.7, respectively. Here we demonstrate the prognostic value for GEP risk stratification in a group of patients primarily treated with novel agents. This trial was registered at www.clinicaltrials.gov as #NCT00098475.


PROVIDER: S-EPMC3204907 | BioStudies | 2011-01-01

REPOSITORIES: biostudies

Similar Datasets

2011-08-25 | E-GEOD-31504 | ArrayExpress
2014-01-01 | S-EPMC3879908 | BioStudies
2011-01-01 | S-EPMC3186329 | BioStudies
2018-11-07 | GSE122231 | GEO
2015-01-01 | S-EPMC4616233 | BioStudies
1000-01-01 | S-EPMC5030385 | BioStudies
2015-01-01 | S-EPMC4530205 | BioStudies
1000-01-01 | S-EPMC5288161 | BioStudies
2013-11-05 | E-GEOD-39816 | ArrayExpress
2016-01-01 | S-EPMC4884414 | BioStudies